SCHEMBL8285454

SCHEMBL8285454

CCOC(=O)C1=C(Cc2ccc(C)cc2)C(=O)c2ccccc2C1=O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 13/20 1.00
LMNA P02545 11/20 1.00
ALDH1A1 P00352 10/20 1.00
HPGD P15428 8/20 1.00
NPSR1 Q6W5P4 8/20 1.00
MEN1 O00255 7/20 1.00
KMT2A Q03164 7/20 1.00
SMN1; SMN2 Q16637 7/20 1.00
TDP1 Q9NUW8 5/20 1.00
HTT P42858 5/20 1.00
ALOX12 P18054 4/20 1.00
PKM P14618 4/20 1.00
STAT3 P40763 1/20 1.00
KCNH2 Q12809 1/20 1.00
KDM4E B2RXH2 8/20 0.81
HKDC1 Q2TB90 4/20 0.81
CCR6 P51684 3/20 0.81
HSP90AA1 P07900 2/20 0.81
KDM4C Q9H3R0 1/20 0.81
TNF P01375 1/20 0.81

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9904910 0.93 MAPT (0.87) MAPTLMNAALDH1A1HPGDNPSR1
SCHEMBL8285456 0.89 MAPT (1.00) MAPTLMNAALDH1A1HPGDNPSR1
SCHEMBL8285453 0.89 MAPT (1.00) MAPTLMNAALDH1A1HPGDNPSR1
SCHEMBL8285451 0.88 MAPT (1.00) MAPTLMNAALDH1A1HPGDNPSR1
SCHEMBL8286963 0.81 MAPT (0.84) MAPTLMNAALDH1A1HPGDNPSR1
SCHEMBL9904567 0.79 MAPT (0.78) MAPTLMNAALDH1A1HPGDNPSR1
SCHEMBL10370782 0.78 MAPT (0.67) MAPTLMNAALDH1A1HPGDNPSR1
SCHEMBL9793702 0.76 MAPT (0.61) MAPTLMNAALDH1A1HPGDNPSR1
SCHEMBL17969801 0.76 MAPT (0.61) MAPTLMNAALDH1A1HPGDNPSR1
SCHEMBL12761935 0.76 TBXAS1 (0.60) MAPTLMNAALDH1A1HPGDNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110257146-A1 Method of Treating Kcnq Related Disorders Using Organozinc Compounds THE JOHNS HOPKINS UNIVERSITY (US) 2011-10-20 US disclosed
US-20110257146-A1 Method of Treating Kcnq Related Disorders Using Organozinc Compounds THE JOHNS HOPKINS UNIVERSITY (US) 2011-10-20 US disclosed
WO-2007087424-A2 METHOD OF TREATING KCNQ RELATED DISORDERS USING ORGANOZINC COMPOUNDS THE JOHNS HOPKINS UNIVERSITY (US) 2007-08-02 WO disclosed
WO-2005053609-A2 METHODS OF NAD+-DEPENDENT DEACETYLASE INHIBITORS GUILFORD PHARMACEUTICALS INC. (US) 2005-06-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110257146-A1 Method of Treating Kcnq Related Disorders Using Organozinc Compounds KCNQ3, KCNQ1, KCNQ5 MAPT 3582/4885LMNA 2368/4885ALDH1A1 2097/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.